Skip to main content

Research Repository

Advanced Search

A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol

Wright, Caroline; Hart, Simon P.; Allgar, Victoria; English, Anne; Swan, Flavia; Dyson, Judith; Richardson, Gerry; Twiddy, Maureen; Cohen, Judith; Hussain, Jamilla; Johnson, Miriam; Hargreaves, Ian; Crooks, Michael G

Authors

Caroline Wright

Simon P. Hart

Victoria Allgar

Anne English

Profile Image

Dr Flavia Swan F.Swan@hull.ac.uk
Research fellow in cancer rehabilitation

Judith Dyson

Gerry Richardson

Judith Cohen

Jamilla Hussain

Ian Hargreaves

Michael G Crooks



Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes breathlessness and cough that worsen over time, limiting daily activities and negatively impacting quality of life. Although treatments are now available that slow the rate of lung function decline, trials of these treatments have failed to show improvement in symptoms or quality of life. There is an immediate unmet need for evidenced-based interventions that improve patients' symptom burden and make a difference to everyday living. This study aims to assess the feasibility of conducting a definitive randomised controlled trial of a holistic, complex breathlessness intervention in people with IPF. Methods and analysis: The trial is a two-centre, randomised controlled feasibility trial of a complex breathlessness intervention compared with usual care in patients with IPF. 50 participants will be recruited from secondary care IPF clinics and randomised 1:1 to either start the intervention within 1 week of randomisation (fast-track group) or to receive usual care for 8 weeks before receiving the intervention (wait-list group). Participants will remain in the study for a total of 16 weeks. Outcome measures will be feasibility outcomes, including recruitment, retention, acceptability and fidelity of the intervention. Clinical outcomes will be measured to inform outcome selection and sample size calculation for a definitive trial. Ethics and dissemination: Yorkshire and The Humber-Bradford Leeds Research Ethics Committee approved the study protocol (REC 18/YH/0147). Results of the main trial and all secondary end-points will be submitted for publication in a peer-reviewed journal. @ERSpublications Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. This study protocol describes the BREEZE-IPF study: a feasibility, randomised controlled trial of a holistic, complex breathlessness intervention in IPF. http://bit.ly/33eF9im Cite this article as: Wright C, Hart SP, Allgar V, et al. A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol.

Citation

Crooks, M. G., Wright, C., Hart, S. P., Allgar, V., English, A., Swan, F., …Crooks, M. G. (2019). A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol. ERJ Open Research, 5(4), https://doi.org/10.1183/23120541.00186-2019

Journal Article Type Article
Acceptance Date Jul 27, 2019
Online Publication Date Oct 22, 2019
Publication Date Oct 22, 2019
Deposit Date Oct 28, 2019
Publicly Available Date Oct 28, 2019
Journal ERJ Open Research
Publisher European Respiratory Society
Peer Reviewed Peer Reviewed
Volume 5
Issue 4
Article Number 0186
DOI https://doi.org/10.1183/23120541.00186-2019
Public URL https://hull-repository.worktribe.com/output/2976162
Publisher URL https://openres.ersjournals.com/content/5/4/00186-2019

Files

Published article (471 Kb)
PDF

Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/

Copyright Statement
Copyright ©ERS 2019
http://creativecommons.org/licenses/by-nc/4.0/
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.





You might also like



Downloadable Citations